quinta-feira, 8 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

Synaptics outlines $290M Q3 revenue guidance as edge AI traction grows and Astra sampling accelerates

View original at seekingalpha.com
Synaptics outlines $290M Q3 revenue guidance as edge AI traction grows and Astra sampling accelerates Earnings Call Insights: Synaptics Incorporated (SYNA) Q2 2026 MANAGEMENT VIEW * CEO Rahul Patel reported strong results, highlighting "total company revenue increased 13% year-over-year, marking our fifth consecutive q…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Astra multimodal microprocessors are seeing strong interest from both customers and partners

    80% confidence
  • Synaptics is not seeing substantial pressure on volumes in mobile and PC categories as of this moment

    80% confidence
  • Channel inventory is very lean and remains very lean and has over the last few quarters

    80% confidence
  • Synaptics will not pursue wireless connectivity in PC market

    80% confidence
  • Production of new Astra products and semi-custom MCU expected end of this quarter or early part of next quarter

    80% confidence
  • The starting backlog for Q4 compared to the same point in time for Q3 is up

    80% confidence
  • Q2 revenue was $302.5 million, above midpoint of guidance and up 13% year-over-year, driven by strength in Core IoT products

    80% confidence
  • While supply constraints are improving, we still see challenges in certain areas

    80% confidence
  • Synaptics is outpacing competitors in integrating Wi-Fi 7 and developing Wi-Fi 8

    80% confidence
  • Q2 non-GAAP gross margin was 53.6%, slightly ahead of guidance midpoint

    80% confidence
  • Astra product revenue contribution is expected to begin in calendar 2027

    80% confidence
  • Synaptics is now sampling silicon for pilot builds of humanoid at a major customer

    80% confidence
  • Non-GAAP operating margin was 19.2%, up approximately 160 basis points sequentially and 190 basis points year-over-year

    80% confidence
  • Performance was driven by 53% year-over-year growth in Core IoT products

    80% confidence
  • Q3 revenue mix expected to be approximately 32% Core IoT, 54% enterprise and automotive, and 14% mobile touch products

    80% confidence
  • Total company revenue increased 13% year-over-year, marking fifth consecutive quarter of double-digit year-over-year growth

    80% confidence
  • Astra as a product category is very accretive to gross margin

    80% confidence
  • Synaptics is seeing early but meaningful traction in robotics with differentiated capabilities across processing, connectivity and sensing

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com